AB-Biotics
Market Cap
€62.5m
Last Updated
2019/12/06 21:50 UTC
Data Sources
Company Financials
Executive Summary
AB-Biotics, S.A. operates as a biotechnology company in Spain.
Snowflake Analysis
Flawless balance sheet with acceptable track record.
Share Price & News
How has AB-Biotics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ABB has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
0%
ABB
-1.2%
ES Biotechs
0.2%
ES Market
1 Year Return
59.2%
ABB
25.3%
ES Biotechs
6.5%
ES Market
Return vs Industry: ABB exceeded the Spanish Biotechs industry which returned 25.3% over the past year.
Return vs Market: ABB exceeded the Spanish Market which returned 6.5% over the past year.
Shareholder returns
| ABB | Industry | Market | |
|---|---|---|---|
| 7 Day | 0% | -1.2% | 0.2% |
| 30 Day | 0.8% | 5.2% | 0.2% |
| 90 Day | 0% | 9.2% | 3.4% |
| 1 Year | 59.2%59.2% | 26.5%25.3% | 10.4%6.5% |
| 3 Year | 208.6%208.6% | 42.7%39.9% | 14.5%3.7% |
| 5 Year | 157.7%157.7% | 89.5%85.2% | 12.7%-6.4% |
Price Volatility Vs. Market
How volatile is AB-Biotics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall St
Who Are The Major Shareholders In AB-Biotics SA (BME:ABB)?1 year ago | Simply Wall St
Why You Need To Look At This Factor Before Buying AB-Biotics SA. (BME:ABB)1 year ago | Simply Wall St
Who Are The Top Investors In AB-Biotics SA. (BME:ABB)?Valuation
Is AB-Biotics undervalued compared to its fair value and its price relative to the market?
26.42x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ABB's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ABB's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ABB is good value based on its PE Ratio (26.4x) compared to the Biotechs industry average (29.2x).
PE vs Market: ABB is poor value based on its PE Ratio (26.4x) compared to the Spanish market (17.2x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ABB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ABB is overvalued based on its PB Ratio (7.9x) compared to the ES Biotechs industry average (4.4x).
Next Steps
Future Growth
How is AB-Biotics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
15.0%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AB-Biotics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine AB-Biotics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- AB-Biotics competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
Past Performance
How has AB-Biotics performed over the past 5 years?
29.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ABB has a high level of non-cash earnings.
Growing Profit Margin: ABB became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: ABB has become profitable over the past 5 years, growing earnings by 29% per year.
Accelerating Growth: ABB has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ABB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).
Return on Equity
High ROE: ABB's Return on Equity (30.1%) is considered high.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is AB-Biotics's financial position?
Financial Position Analysis
Short Term Liabilities: ABB's short term assets (€7.2M) exceed its short term liabilities (€3.5M).
Long Term Liabilities: ABB's short term assets (€7.2M) exceed its long term liabilities (€4.1M).
Debt to Equity History and Analysis
Debt Level: ABB's debt to equity ratio (2.3%) is considered satisfactory.
Reducing Debt: ABB had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: ABB's debt is well covered by operating cash flow (223.4%).
Interest Coverage: ABB's interest payments on its debt are well covered by EBIT (6.6x coverage).
Balance Sheet
Inventory Level: ABB has a low level of unsold assets or inventory.
Debt Coverage by Assets: ABB's debt is covered by short term assets (assets are 39.3x debt).
Next Steps
Dividend
What is AB-Biotics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate ABB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ABB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ABB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ABB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ABB's dividend in 3 years as they are not forecast to pay a notable one for the Spanish market.
Next Steps
Management
What is the CEO of AB-Biotics's salary, the management and board of directors tenure and is there insider trading?
CEO
Sergi Audivert Brugué 0
0yrs
Tenure
Mr. Sergi Audivert Brugué serves as a Co-Founder, Co-Chief Executive Officer and Director at AB-Biotics SA and served as its Chief Operating Officer. Mr. Audivert serves as Chairman of AB-Biotics S.A. Mr. ...
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Miquel Àngel Bonachera Sierra
Co-Founder
- Tenure: 0yrs
Sergi Audivert Brugué
Co-Founder
- Tenure: 0yrs
Carlos de Lecea
Managing Director
- Tenure: 0yrs
José María de Paz
Non-Board Secretary
- Tenure: 0yrs
Mercè Mengual
Marketing Director
- Tenure: 0yrs
Jordi Riera
Chief Business Development Officer
- Tenure: 0yrs
Mario Saldanha
Chief Financial Officer
- Tenure: 0.9yrs
Board Members
Shinji Mizusawa
Director
- Tenure: 0yrs
Miquel Àngel Bonachera Sierra
Co-Founder
- Tenure: 0yrs
Sergi Audivert Brugué
Co-Founder
- Tenure: 0yrs
Kazuhiko Fujii
Director
- Tenure: 0yrs
Hitoshi Yahara
Director
- Tenure: 0yrs
Juan Ramón Ramos Raich
Independent Director
- Tenure: 0yrs
José María Echarri Torres
Independent Director
- Tenure: 0yrs
Philip Claes
Director
- Tenure: 0yrs
Agustí Vilajoana Mas
Independent Director
- Tenure: 0yrs
Company Information
AB-Biotics, S.A.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: AB-Biotics, S.A.
- Ticker: ABB
- Exchange: BME
- Founded: 2004
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €62.545m
- Shares outstanding: 12.51m
- Website: https://www.ab-biotics.com
Number of Employees
Location
- AB-Biotics, S.A.
- ESADE CREAPOLIS BUSINESS PARK
- Avinguda de la Torre Blanca, 57, OFFICE 3B11
- Barcelona
- Catalonia
- 8172
- Spain
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ABB | BME (Bolsas y Mercados Espanoles) | Yes | Series A shares | ES | EUR | Jul 2010 |
Biography
AB-Biotics, S.A. operates as a biotechnology company in Spain. The company offers probiotic products, including cardiometabolic products comprising AB-LIFE; oral care products that include AB-Dentalac and ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/06 21:50 |
| End of Day Share Price | 2019/11/22 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.